ASP Isotopes Secures $22M Loan for Uranium Facility

ASP Isotopes, Inc. ( (ASPI) ) has issued an update.

On May 19, 2025, ASP Isotopes Inc. announced a loan agreement with TerraPower to finance the construction of a new uranium enrichment facility in South Africa. The agreement includes a $22 million loan to support the production of HALEU, with TerraPower as a future customer. This development positions ASP Isotopes to enhance its market presence in the nuclear sector, with significant supply agreements valued at up to $3.75 billion over a decade, potentially impacting its operations and stakeholder interests.

The most recent analyst rating on (ASPI) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.

Spark’s Take on ASPI Stock

According to Spark, TipRanks’ AI Analyst, ASPI is a Neutral.

The overall stock score is driven by a combination of strong technical momentum and strategic operational developments, balanced by significant financial challenges and valuation concerns. The absence of profitability and cash flow generation are major risks, while future growth prospects and cash reserves provide some optimism.

To see Spark’s full report on ASPI stock, click here.

More about ASP Isotopes, Inc.

ASP Isotopes Inc. is a company involved in the nuclear industry, focusing on the production of High Assay Low-Enriched Uranium (HALEU) through uranium enrichment facilities. The company is working on establishing a new uranium enrichment facility in South Africa, utilizing its proprietary technology.

Average Trading Volume: 2,102,477

Technical Sentiment Signal: Buy

Current Market Cap: $525.4M

For a thorough assessment of ASPI stock, go to TipRanks’ Stock Analysis page.